Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Rinvoq is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) Rinvoq is the first and only JAK inhibitor approved for both active ankylosing spondylitis (AS) and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news